A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2002
11/21/2002	WO2002092826A2 Composition and method for treating cancer using herpes virus
11/21/2002	WO2002092808A1 Random gene unidirectional antisense library
11/21/2002	WO2002092807A1 Unigene unidirectional antisense library
11/21/2002	WO2002092796A1 Papilloma pseud-virus and it's preparation
11/21/2002	WO2002092788A2 Cytotoxic peptides and peptidomimetics based thereon, and methods for use thereof
11/21/2002	WO2002092782A2 Diagnosis and treatment of malignant neoplasms
11/21/2002	WO2002092779A2 Method for enriching tissues in long chain polyunsaturated fatty acids
11/21/2002	WO2002092772A2 Antisense modulation of ptp1b expression
11/21/2002	WO2002092617A1 Combined approach to treatment of cancer using a c-myc antisense oligomer
11/21/2002	WO2002092616A1 Antisense permeation enhancers
11/21/2002	WO2002092614A1 Novel 5-thio-ss-d-xylopyranoside derivatives, preparation method thereof, pharmaceutical compositions containing same and the therapeutic use thereof
11/21/2002	WO2002092606A1 Fused imidazolidine derivatives, process for preparation of the same and use thereof
11/21/2002	WO2002092605A1 CRYSTAL OF HYDRATE OF ß-LACTAM COMPOUND
11/21/2002	WO2002092604A1 1-oxa-3,9-diaza-spiro'5,5!undecan-2-ones derivatives and its use as antagonist of the neurikinin receptor
11/21/2002	WO2002092603A1 Oxazolo-and furopyrimidines and their use in medicaments against tumors
11/21/2002	WO2002092600A1 Retinol derivatives potentiation of active substances by micellar preparation
11/21/2002	WO2002092599A1 4-amino-5-phenyl-7-cyclobutyl-pyrrolo (2,3-d) pyrimidine derivatives
11/21/2002	WO2002092598A1 DIHYDROIMIDAZO [5,1-A]-$G(b)-CARBOLINE DERIVATIVES, METHOD FOR PREPARING SAME AND USE THEREOF AS MEDICINE
11/21/2002	WO2002092597A1 The citrate salt of 5, 8, 14-triazatetracyclo(10.3.1.0?2,11.04.9¿)-hexadeca-2.(11),3,5,7,9-pentaene and pharmaceutical compositions thereof
11/21/2002	WO2002092596A1 Novel sulfonate substituted pyrazol pyridine dervivatives
11/21/2002	WO2002092595A1 Broadspectrum 2-amino-benzoxazole sulfonamide hiv protease inhibitors
11/21/2002	WO2002092594A1 Substituted 4h-chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof
11/21/2002	WO2002092593A1 4-(4-pyridazinyl)pyrazole derivatives
11/21/2002	WO2002092592A1 Novel 1-amidomethylcarbonyl-piperidine derivatives, method and intermediate products for the production thereof and medicament containing said compounds
11/21/2002	WO2002092590A1 Furan and thiophene derivatives that activate human peroxisome proliferator activated receptors
11/21/2002	WO2002092589A2 Novel decalactones from associated fungi of marine sponges and their synthetic derivatives as medicaments
11/21/2002	WO2002092588A2 Aromatic sulfone hydroxamates and their use as protease inhibitors
11/21/2002	WO2002092585A1 Novel, arylsusfonamide compounds for the treatment of obesity, type ii diabetes and cns-disorders
11/21/2002	WO2002092576A1 Diarylurea derivatives useful as anti-inflammatory agents
11/21/2002	WO2002092573A2 Heterocyclic substituted pyrazoles as inhibitors of src and other protein kinases
11/21/2002	WO2002092571A1 Novel 4-anilinoquinoline-3-carboxamides
11/21/2002	WO2002092568A1 5-cyano-1h-indole derivatives as antagonists of the interleukine-8 receptors
11/21/2002	WO2002092567A1 Novel 5-phenyl-1h-indole derivatives as antagonists of interleukine-8 receptors
11/21/2002	WO2002092566A1 Arginine derivatives
11/21/2002	WO2002092565A2 3-aminoalkyl-2-aryl-indole derivatives and their use as gnrh antagonists
11/21/2002	WO2002092563A2 Protease inhibitors
11/21/2002	WO2002092558A1 Polythiourea lipid derivatives
11/21/2002	WO2002092556A1 Sulfonamide derivatives
11/21/2002	WO2002092554A1 Complexes for transferring substances of interest into a cell
11/21/2002	WO2002092553A1 Hydroxamic acids and acyl hydroxamines as naaladase inhibitors
11/21/2002	WO2002092552A2 Benzamidoacetonitriles and their use as antiparasitics
11/21/2002	WO2002092550A1 Thyroid hormone receptor antagonists for cardiac and metabolic disorders ii
11/21/2002	WO2002092540A1 Production and use of a polar lipid-rich fraction containing omega-3 and/or omega-6 highly unsatruated fatty acids from microbes, genetically modified plant seeds and marine organisms
11/21/2002	WO2002092139A1 Methods for inactivating viruses
11/21/2002	WO2002092129A2 Pharmaceutical combination comprising an anti-androgen and an oestrogen receptor beta agonist
11/21/2002	WO2002092126A1 Binding member which binds to both lewis-y and lewis-b haptens, and its use for treating cancer
11/21/2002	WO2002092122A2 Use of osteopontin for the treatment and/or prevention of neurologic diseases
11/21/2002	WO2002092116A1 Targeted delivery of drugs for the treatment of viral infections
11/21/2002	WO2002092114A1 Preventives and/or remedies for fish infections
11/21/2002	WO2002092113A1 Alcoholic valerian extract for improving sleep quality and efficiency, and methods of preparing it
11/21/2002	WO2002092112A1 Oral supplement
11/21/2002	WO2002092111A1 Use of extracts and preparations from iris plants and tectorigenin as medicaments
11/21/2002	WO2002092110A1 New use of natural plant polyphenol and medicament and/or health care product containing natural plant polyphenol
11/21/2002	WO2002092107A1 Method and compositions for treating mammalian nerve tissue injuries
11/21/2002	WO2002092106A1 Taste masking pharmaceutical composition
11/21/2002	WO2002092105A1 Composition containing s-adenosylmethionine for treating or preventing insulin resistance syndrome
11/21/2002	WO2002092104A1 A pharmaceutical composition comprising lysophosphatidic acid
11/21/2002	WO2002092103A1 Chemoprotection using amifostine and related compounds
11/21/2002	WO2002092102A2 Treatment of conditions relating to hormone deficiencies by administration of progestins
11/21/2002	WO2002092100A1 17-(c(ch3) (ch2) o-3c (r4, r5) n (r6, r7))-substituted 19-nor-pregna-1, 3, 5(10)-triene derivatives and their medical use
11/21/2002	WO2002092099A1 Prostanoic acid derivatives as agents for lowering intraocular pressure
11/21/2002	WO2002092098A1 Method for treating ocular hypertension and glaucoma
11/21/2002	WO2002092097A1 Composition comprising phosphodiesterase inhibitors for inducing cervical ripening
11/21/2002	WO2002092096A1 Antitumor agents
11/21/2002	WO2002092095A1 Use of nevirapine to treat or prevent lipid pathology in patients with hiv that is resistant to nevirapine
11/21/2002	WO2002092094A1 Crystalline isoxazole derivative and medical preparation thereof
11/21/2002	WO2002092093A1 Adenosine analogues for the treatment of the insulin resistance syndrome and diabetes
11/21/2002	WO2002092092A1 Minoxidil-containing liquid composition
11/21/2002	WO2002092091A1 Combination comprising n-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent
11/21/2002	WO2002092090A1 Substituted pyrazinones, pyridines and pyrimidines as corticotropin releasing factor ligands
11/21/2002	WO2002092089A1 Tartrate salts of 5,8,14-triazatetracyclo {10.3.1.0?2,11.04,9¿}-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof
11/21/2002	WO2002092088A2 Novel use of 2h-benzimidazol-2-one, 1,3-dihadro-1-(2{4-{3-(trifluoromethyl}phenyl]-1-piperazinyl}ethyl)- and its physiologically acceptable acid addition salts
11/21/2002	WO2002092087A1 2,5-disubstituted pyridine, pyrimidine, pyridazine and 1, 2, 4-triazine derivatives for use as p38 inhibitors
11/21/2002	WO2002092086A1 Imidazo (1,2-a)-pyridine derivatives as mglur5 antagonists
11/21/2002	WO2002092085A1 Pharmaceutical compositions comprising chelidonine or derivatives thereof
11/21/2002	WO2002092084A1 Carboxylic acid substituted oxazole derivatives for use as ppar-alpha and -gamma activators in the treatment of diabetes
11/21/2002	WO2002092083A1 7,8-fused 4$i(h)-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof
11/21/2002	WO2002092082A1 Stable high-concentration injection containing pyrazolone derivative
11/21/2002	WO2002092080A1 Methods and compositions for treat lung diseases
11/21/2002	WO2002092079A1 Utilization of selective indirubin derivatives as vegf-r inhibitors
11/21/2002	WO2002092078A1 Oral controlled release pharmaceutical composition for one-a-day therapy for the treatment and prophylaxis of cardiac and circulatory diseases
11/21/2002	WO2002092077A2 Use of lipoic acid for suppressing undesired haematological effects of chemotherapy and/or radiotherapy
11/21/2002	WO2002092076A1 Substituted coumarins and quinolines as caspases activators
11/21/2002	WO2002092075A2 Therapeutic delivery of carbon monoxide
11/21/2002	WO2002092074A1 Remedial agent for myelopathic disease
11/21/2002	WO2002092073A1 Production and use of a polar lipid-rich fraction containing stearidonic acid and gamma linolenic acid from plant seeds and microbes
11/21/2002	WO2002092072A2 Drugs for the treatment of the alzheimer disease
11/21/2002	WO2002092071A1 Novel treatment for obsessive-compulsive disorder (ocd) and ocd-related disorders using gvg
11/21/2002	WO2002092070A1 Isostearic acid salts as permeation enhancers
11/21/2002	WO2002092069A1 Permeation enhancers
11/21/2002	WO2002092068A1 Carboxylic acid derivatives and drugs containing the same as the active ingredient
11/21/2002	WO2002092067A1 Compositions for transmucosal administration containing coenzyme q as the active ingredient
11/21/2002	WO2002092066A1 Antitumor preparation devoid of side effect
11/21/2002	WO2002092065A2 Novel methods for the treatment and prevention of pain using stress-activated protein kinase inhibitors
11/21/2002	WO2002092064A2 Therapeutic method for inducing tolerance
11/21/2002	WO2002092063A2 Utilization of rutins and aescins in the treatment of ocular circulatory disturbances
11/21/2002	WO2002092062A2 Combination of vitamin d analogue and pyrimidine nucleoside analogue
11/21/2002	WO2002092060A1 Abuse-resistant controlled-release opioid dosage form
11/21/2002	WO2002092059A1 Abuse-resistant opioid dosage form
11/21/2002	WO2002092056A1 Compaction process for manufacture of sodium phenytoin dosage form

1 ... 5642 5643 5644 5645 5646 5647 5648 5649 5650 5651 5652 5653 5654 5655 5656 5657 5658 5659 5660 5661 5662 ... 7860